OA10341A - Anti-hiv triple combination - Google Patents

Anti-hiv triple combination Download PDF

Info

Publication number
OA10341A
OA10341A OA60946A OA60946A OA10341A OA 10341 A OA10341 A OA 10341A OA 60946 A OA60946 A OA 60946A OA 60946 A OA60946 A OA 60946A OA 10341 A OA10341 A OA 10341A
Authority
OA
OAPI
Prior art keywords
zidovudine
combination
loviride
htv
ciaims
Prior art date
Application number
OA60946A
Other languages
English (en)
Inventor
Paulus Aloysius Maria Stoffels
Koenraad Jozef Lodewij Andries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of OA10341A publication Critical patent/OA10341A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
OA60946A 1994-07-01 1996-12-31 Anti-hiv triple combination OA10341A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94201897 1994-07-01

Publications (1)

Publication Number Publication Date
OA10341A true OA10341A (en) 1997-10-07

Family

ID=8217000

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60946A OA10341A (en) 1994-07-01 1996-12-31 Anti-hiv triple combination

Country Status (25)

Country Link
EP (1) EP0768881B1 (cs)
JP (1) JP2945481B2 (cs)
KR (1) KR100218495B1 (cs)
CN (1) CN1091599C (cs)
AP (1) AP9600896A0 (cs)
AT (1) ATE218867T1 (cs)
AU (1) AU693911B2 (cs)
BG (1) BG101175A (cs)
BR (1) BR9508201A (cs)
CA (1) CA2193489A1 (cs)
CZ (1) CZ375596A3 (cs)
DE (1) DE69527066T2 (cs)
EE (1) EE9600180A (cs)
FI (1) FI965292A0 (cs)
HU (1) HUT77720A (cs)
IL (1) IL114415A0 (cs)
MX (1) MX9700044A (cs)
MY (1) MY130597A (cs)
NO (1) NO965556D0 (cs)
OA (1) OA10341A (cs)
PL (1) PL317891A1 (cs)
SK (1) SK168196A3 (cs)
TW (1) TW401303B (cs)
WO (1) WO1996001110A2 (cs)
ZA (1) ZA955471B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE131730T1 (de) * 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen

Also Published As

Publication number Publication date
MY130597A (en) 2007-07-31
CZ375596A3 (en) 1997-04-16
NO965556L (no) 1996-12-23
JPH09507858A (ja) 1997-08-12
CN1151697A (zh) 1997-06-11
BR9508201A (pt) 1997-11-11
FI965292A7 (fi) 1996-12-31
BG101175A (bg) 1997-08-29
FI965292L (fi) 1996-12-31
SK168196A3 (en) 1997-05-07
NO965556D0 (no) 1996-12-23
DE69527066D1 (de) 2002-07-18
FI965292A0 (fi) 1996-12-31
HU9603627D0 (en) 1997-02-28
EE9600180A (et) 1997-06-16
MX9700044A (es) 1997-04-30
JP2945481B2 (ja) 1999-09-06
TW401303B (en) 2000-08-11
ATE218867T1 (de) 2002-06-15
AU2924895A (en) 1996-01-25
IL114415A0 (en) 1995-10-31
WO1996001110A2 (en) 1996-01-18
WO1996001110A3 (en) 1996-02-22
CN1091599C (zh) 2002-10-02
ZA955471B (en) 1996-12-30
PL317891A1 (en) 1997-04-28
CA2193489A1 (en) 1996-01-18
KR100218495B1 (en) 1999-09-01
HUT77720A (hu) 1998-07-28
DE69527066T2 (de) 2003-02-13
EP0768881A2 (en) 1997-04-23
AU693911B2 (en) 1998-07-09
AP9600896A0 (en) 1997-01-31
EP0768881B1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
JP4335311B2 (ja) プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
Cameron et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
Jacobson et al. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS
Shelton et al. Didanosine
Groopman Current advances in the diagnosis and treatment of AIDS: an introduction
Ichimura et al. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus
US7919101B2 (en) Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors
EP0768881B1 (en) Anti-hiv triple combination comprising zidovudine, lamivudine and loviride
JPH03505579A (ja) ヒト免疫不全ウイルス（ｈｉｖ）のインビボにおける活性の阻害方法
McCabe et al. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment
Pollard Use of proteinase inhibitors in clinical practice
US6787573B2 (en) Antiviral therapy
JPH02501220A (ja) 芳香族多環式ジオンを含有する抗ウイルス性薬剤及びレトロウイルス感染治療方法
Acosta et al. Agents for treating human immunodeficiency virus infection
Humphrey et al. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection
Hitchcock In vitro antiviral activity of didanosine compared with that of other dideoxynucleoside analogs against laboratory strains and clinical isolates of human immunodeficiency virus
Blanche et al. Randomized study of two doses of didanosine in children infected with human immunodeficiency virus
Friedland et al. Stavudine (d4T, Zerit®)
Robertson‐Dallas et al. New drug interactions with zidovudine
Kahn The clinical use of didanosine
Fletcher Current perspectives on antiretroviral therapy
WO1989009055A1 (en) Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
WO1989002741A1 (en) Inhibitors of hiv-reverse transcriptase to treat aids
AU1133899A (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
WO1989002741A2 (en) Inhibitors of hiv-reverse transcriptase to treat aids